Efficacy of current treatments against hepatitis C virus


  • Jose M. Zepeda School of Medicine, Autonomous University of Guadalajara, Guadalajara, Jalisco, Mexico
  • Alejandro Murrieta School of Medicine, Autonomous University of Guadalajara, Guadalajara, Jalisco, Mexico
  • Javier Contreras School of Medicine, Autonomous University of Guadalajara, Guadalajara, Jalisco, Mexico
  • Felix Osuna School of Medicine, Autonomous University of Guadalajara, Guadalajara, Jalisco, Mexico
  • Luis Antonio Villalobos Calderon School of Medicine, Autonomous University of Guadalajara, Guadalajara, Jalisco, Mexico
  • Miriam Pérez School of Medicine, University of the valley of Mexico, Guadalajara, Jalisco, Mexico
  • María Holanda García Ramírez School of Medicine, Vasco de Quiroga University, Morelia, Michoacán, Mexico
  • Omar De J. Dorantes School of Medicine, Autonomous University of Querétaro, Querétaro, Querétaro, Mexico




Hepatitis C virus, Chronic hepatitis, Treatment and drugs


It is estimated that currently, in the world, approximately 3% of the population has chronic hepatitis, the hepatitis C virus is the etiological agent most related to the development of this pathology. The diversity of genotypes (7) and quasi-species of HCV, due to its high mutation rate, interferes with an effective humoral immunity. The aim of this work is precisely to evoke those usual drugs used in HCV therapy, as well as cutting-edge drugs. The goal of treatment is the eradication of HCV infection. One strategy offered by the WHO is to eradicate the virus in at-risk populations. Alternatives to the previously used treatment with interferon and ribavirin are shown in this paper; protease inhibitors and other targets have now been developed to make eradication of the virus more effective.


Greenberger N, Blumberg R, Burakoff R. Diagnóstico y tratamiento en gastroenterología, hepatología y endoscopia. 1st ed. México: McGraw-Hill. 2011: 212-299.

Arias Rebatet G, León Jiménez R, McPhee S, Papadakis M, Pérez Tamayo A, Rabow M. Diagnóstico clínico y tratamiento 2017. 56th ed. México: McGraw Hill Education. 2017: 600-663.

Fauci A, Jameson J, Kasper D. Harrison Principios de medicina interna. 20th ed. México D. F. McGraw-Hill. 2018: 2375-2399.

Loustaud-Ratti V, Debette-Gratien M, Jacques J, Alain S, Marquet P, Sautereau D, Rousseau A, Carrier P. Ribavirin: Past, present and future. World J hepatol. 2016;8(2):123.

Fourati S, Rodriguez C, Hézode C, Soulier A, Ruiz I, Poiteau L et al. Frequent antiviral treatment failures in patients infected with hepatitis C virus genotype 4, subtype 4r. Hepatology. 2019;69(2):513-23.

Williford SE, McGivern DR. Mechanism of Action of Direct-Acting Antivirals: New Insights into the HCV Life Cycle. InHepatitis C Virus II Springer, Tokyo. 2016;287-301.

Hessel MH, Cohen AF, Rissmann R. Sofosbuvir and daclatasvir. Brit J Clin pharmacol. 2016;82(3):878.

Asselah T, Marcellin P, Schinazi RF. Treatment of hepatitis C virus infection with direct-acting antiviral agents: 100% cure? Liver Int. 2018;38(1):7-13.

Butler K, Larney S, Day C, Burns L. Uptake of direct acting antiviral therapies for the treatment of hepatitis C virus among people who inject drugs in a universal health-care system. Drug and Alcohol Review. Sydney: Australasian Professional Society on Alcohol and other Drugs. 2018;1-6.

Cacoub P, Si Ahmed S, Ferfar Y, Pol S, Thabut D, Hezode C et al. Long-Term Efficacy of Interferon-Free Antiviral Treatment Regimens in PatientsWith Hepatitis C Virus-Associated Cryoglobulinemia Vasculitis. Clin Gastroenterol Hepatol Paris AGA Institute. 2018;1-9.

Sanford M. Simeprevir: a review of its use in patients with chronic hepatitis C virus infection. Drugs. 2015;75(2):183-96.

Bartlett S, Fox P, Cabatingan H, Jaros A, Gorton C, Lewis R et al. Demonstration of Near-Elimination of Hepatitis C Virus Among a Prison Population. The Lotus Glen Correctional Centre Hepatitis C Treatment Project. IDSA. Oxford: Oxford University. 2018; 460-3.

Gupta N, Mbituyumuremyi A, Kabahizi J, Ntganda F, Muvunyi C, Shumbusho F et al. Treatment of chronic hepatitis C virus infection in Rwanda with ledipasvir-sofosbuvir (SHARED): a single-arm trial. Gilead Sciences. Boston: Elsevier. 2018;1-8.

Nitulescu R, Young J, Saeed S. Variation in hepatitis C virus treatment uptake between Canadian centres in the era of direct-acting antivirals. Int J Drug Policy. 2019;65:41-9.

Pourmarzi D, Hall L, Hepworth J, Smirnov A, Rahman T, FitzGerald G. Clinical effectiveness, cost effectiveness and acceptability of community-based treatment of hepatitis C virus infection: A mixed method systematic review. JVH. 2018;26:432-53.

Woodward EN, Matthieu MM, Uchendu US, Rogal S, Kirchner JE. The health equity implementation framework: proposal and preliminary study of hepatitis C virus treatment. IS. 2019;14(27):1-18.

Spengler U. Direct antiviral agents (DAAs)-a new age in the treatment of hepatitis C virus infection. Pharmacol Therapeutics. 2018;183:118-26.

SWei L, Lim S, Xie Q, Pratvisuth T, Huang Y, Wu S et al. Sofosbuvir-velpatasvir for treatment of chronic hepatitis C virus infection in Asia: a single-arm, open-label, phase 3 trial. Gilead Sciences. Shanghai: Elsevier. 2018;1-7.

Wyles D, Weiland O, Yao B, Reindollar R, Weilert F, Dufour JF et al. Retreatment of patients who failed glecaprevir/pibrentasvir treatment for hepatitis C virus infection. J Hepatol. 2018;68:S23-4.

Brenner G, Stevens C. Farmacología básica, 5th ed. Barcelona. Elsevier España. 2019: 401-407.




How to Cite

Zepeda, J. M., Murrieta, A., Contreras, J., Osuna, F., Calderon, L. A. V., Pérez, M., Ramírez, M. H. G., & Dorantes, O. D. J. (2022). Efficacy of current treatments against hepatitis C virus. International Journal of Basic & Clinical Pharmacology, 11(2), 191–196. https://doi.org/10.18203/2319-2003.ijbcp20220024



Review Articles